NOVADAQ Announces Completion of Plan of Arrangement
Sep 01, 2017 12:04 pm UTC| Business
TORONTO, Sept. 01, 2017 -- NOVADAQ Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ) (“NOVADAQ” or the “Corporation”) today announced completion of its previously announced plan of arrangement under the Canada Business...
MediWound Successfully Completes Second Cohort of EscharEx® Phase 2 Study
Sep 01, 2017 12:00 pm UTC| Business
YAVNE, Israel, Sept. 01, 2017 -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports positive...
Intellipharmaceutics Appoints New Chief Financial Officer
Sep 01, 2017 12:00 pm UTC| Business
TORONTO, Sept. 01, 2017 -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture...
Altisource Residential Corporation Provides Update on Impact of Hurricane Harvey
Sep 01, 2017 12:00 pm UTC| Business
CHRISTIANSTED, U.S. Virgin Islands, Sept. 01, 2017 -- Altisource Residential Corporation (“RESI” or the “Company”) (NYSE:RESI) announced today that preliminary reports indicate that Hurricane Harvey is likely to have a...
Sep 01, 2017 12:00 pm UTC| Business
HUNTINGTON BEACH, Calif., Sept. 01, 2017 -- BJ’s Restaurants, Inc. (NASDAQ:BJRI) today announced that it will aid the victims of Hurricane Harvey with the help of its guests and team members nationwide. Every Tuesday,...
Jostens and College Football Playoff Renew Partnership to Present National Championship Game Rings
Sep 01, 2017 12:00 pm UTC| Business
MINNEAPOLIS, Sept. 01, 2017 -- Just in time for the kick off of the 2017-18 college football season, the College Football Playoff (CFP) has renewed its partnership with Jostens to create its College Football Playoff...
Fate Therapeutics to Present at Upcoming Investor Conferences
Sep 01, 2017 12:00 pm UTC| Business
SAN DIEGO, Sept. 01, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that...